The report on Global Suture Equipment Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic definition []
The report on Global Biological Implants Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic definition []
The report on Global Hemostatic and Tissue Sealing Agents Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains []
The report titled Global Polysaccharide Hemostatic Agents Market is one of the most comprehensive and important additions to QY Researchs archive of market research studies. It offers detailed research and analysis of key aspects of the global Polysaccharide Hemostatic Agents market. The market analysts authoring this report have provided in-depth information on leading growth []
Tissue Glue and Bio-adhesive Sealants Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied []
Major players in the soft tissue repair market are Organogenesis Inc. , Stryker Corporation, Johnson & Johnson, Arthrex Inc, CryoLife Inc. , Integra Lifesciences Corporation, Wright Medical Technology, Smith & Nephew plc, C. Major players in the soft tissue repair market are Organogenesis Inc. , Stryker Corporation, Johnson & Johnson, Arthrex Inc, CryoLife Inc. , Integra Lifesciences Corporation, Wright Medical Technology, Smith & Nephew plc, C.
Stay up-to-date with Regenerative Medicine Market research offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth.
A2Z Market Research announces the release of the Aortic Valve Replacement Devices Market research report. The market is predicted to grow at a healthy pace in the coming years. Aortic Valve Replacement Devices Market 2021 research report presents an analysis of market size, share, and growth, trends, cost structure, statistical and comprehensive data of the global []
CryoLife with ticker code (CRY) have now 3 analysts in total covering the stock. The consensus rating is ''Strong_Buy''. The target price ranges between 38 and 30.75 and has a mean target at 34.58. With the stocks previous close at 28.7 this would indicate that there is a potential upside of 20.5%. The 50 day moving average now sits at 29.23 while the 200 day moving average is 25.73. The company has a market cap of $1,122m. You can visit the company''s website by visiting: /> [stock_market_widget type="chart" symbol="CRY" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] CryoLife manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X prosthetic aortic and mitral heart valve, and On-X ascending aortic prosthesis; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS and E-vita OPEN NEO, a hybrid stent graft system.
CryoLife with ticker code (CRY) now have 3 analysts covering the stock with the consensus suggesting a rating of ''Strong_Buy''. The range between the high target price and low target price is between 38 and 30.75 with the average target price sitting at 34.58. Given that the stocks previous close was at 28.46 this would indicate that there is a potential upside of 21.5%. The 50 day MA is 29.4 while the 200 day moving average is 25.23. The market cap for the company is $1,141m. Find out more information at: /> [stock_market_widget type="chart" symbol="CRY" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] CryoLife manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X prosthetic aortic and mitral heart valve, and On-X ascending aortic prosthesis; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS and E-vita OPEN NEO, a hybrid stent graft system.
CryoLife found using ticker (CRY) now have 3 analysts in total covering the stock. The consensus rating is ''Strong_Buy''. The target price ranges between 38 and 30.75 with a mean TP of 34.58. Given that the stocks previous close was at 28.89 this would indicate that there is a potential upside of 19.7%. The day 50 moving average is 27.8 and the 200 day moving average is 24.65. The market capitalisation for the company is $1,131m. Find out more information at: /> [stock_market_widget type="chart" symbol="CRY" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] CryoLife manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X prosthetic aortic and mitral heart valve, and On-X ascending aortic prosthesis; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS and E-vita OPEN NEO, a hybrid stent graft system.
CryoLife with ticker code (CRY) now have 3 analysts in total covering the stock. The consensus rating is ''Strong_Buy''. The target price ranges between 38 and 30.75 and has a mean target at 34.58. With the stocks previous close at 29.21 this indicates there is a potential upside of 18.4%. The day 50 moving average is 26.94 while the 200 day moving average is 24.36. The company has a market capitalisation of $1,126m. Company Website: /> [stock_market_widget type="chart" symbol="CRY" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] CryoLife manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X prosthetic aortic and mitral heart valve, and On-X ascending aortic prosthesis; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS and E-vita OPEN NEO, a hybrid stent graft system.
The Latest research study released by CMI "Global Tissue and Organ Transplantation Market" with 360+ pages of analysis on business Strategy taken up by key and emerging industry players and delivers know how of the current market development, landscape, technologies,
Allied Market Research (USA, Oregon, Portland) Published Latest Report titled, Cardiac Valve Market: Global Opportunity Analysis and Industry Forecast 2020-2027. This market research study determines the increase in changes and the aspects which are likely to have an impact on the
Allied Market Research (USA, Oregon, Portland) Published Latest Report titled, Cardiac Valve Market: Global Opportunity Analysis and Industry Forecast 2020-2027. This market research study determines the increase in changes and the aspects which are likely to have an impact on the
Allied Market Research (USA, Oregon, Portland) Published Latest Report titled, Cardiac Valve Market: Global Opportunity Analysis and Industry Forecast 2020-2027. This market research study determines the increase in changes and the aspects which are likely to have an impact on the
Latest released the research study on Global Structural Heart Devices Market, offers a detailed overview of the factors influencing the global business scope. Structural Heart DevicesMarket research report shows the latest market insights, current situation analysis with upcoming trends and breakdown of the products and services. The report provides key statistics on the market status, []
CryoLife with ticker code (CRY) have now 3 analysts in total covering the stock. The consensus rating is ''Strong_Buy''. The range between the high target price and low target price is between 38 and 30.75 with a mean TP of 34.58. With the stocks previous close at 31.53 this now indicates there is a potential upside of 9.7%. The 50 day MA is 25.98 while the 200 day moving average is 23.95. The company has a market cap of $1,169m. Visit the company website at: /> [stock_market_widget type="chart" symbol="CRY" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] CryoLife manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X prosthetic aortic and mitral heart valve, and On-X ascending aortic prosthesis; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS and E-vita OPEN NEO, a hybrid stent graft system.
The newly developed market research study on Global Wound Care Sealants Market Growth 2020-2025 presents a profound comprehension regarding the functioning and expansion of the market on a regional and global level. The report contains broad information relating to the market statistics such as market size, growth rate, research and development activities, new product launches []
CryoLife with ticker code (CRY) have now 3 analysts covering the stock. The analyst consensus points to a rating of ''Strong_Buy''. The target price ranges between 38 and 30.75 with a mean TP of 34.58. With the stocks previous close at 28.99 this now indicates there is a potential upside of 19.3%. The day 50 moving average is 24.91 while the 200 day moving average is 23.53. The company has a market cap of $1,136m. You can visit the company''s website by visiting: /> [stock_market_widget type="chart" symbol="CRY" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] CryoLife manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X prosthetic aortic and mitral heart valve, and On-X ascending aortic prosthesis; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS and E-vita OPEN NEO, a hybrid stent graft system.
Overstock.com, Aon, Cryolife, AstraZeneca, Cryolife and Mesoblast are five stock gainers for Friday.
Cardiac Prosthetic Devices Market report is an in-depth analysis study offered which explains necessary aspects like competition, segmentation, and regional growth in excessive detail. As a part of competitive analysis, the analysis study includes thorough company identification of leading players
ATLANTA, March 9, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming Oppenheimer 31st Annual Virtual Healthcare conference on Tuesday, March 16 - 17, 2021. The…
Vascular patches are the microporous patch of bio-compatible polyester-urethane patches which are used for vascular surgeries for suturing closure. According to the World Health Organization (WHO), cardiovascular diseases are the leading cause of deaths, claiming approximately 17.9 million lives every
ATLANTA, Feb. 11, 2021 /PRNewswire/ -- Fourth Quarter and Recent Business Highlights: Achieved total revenues of $67.9 million in the fourth quarter 2020 versus $69.7 million in the fourth quarter of 2019 Total revenues decreased 3% on a GAAP basis and 5% on a non-GAAP proforma constant…
SMI has recently published a research report titled, “Global Specialty Surgical Wound Care Products Market Report 2020“. This report has been prepared by experienced and knowledgeable market analysts and researchers. It is a phenomenal compilation of important research studies that
DUBLIN, Dec. 30, 2020 /PRNewswire/ -- The "Hemostasis and Tissue Sealing Agents Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020" report has been added to ResearchAndMarkets.com's offering. This report on the global hemostasis and tissue sealing…
ATLANTA, Nov. 19, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will host a webcast for investors and analysts to discuss progress with the Company's ongoing PROACT Xa trial on December 7,…
Hemostats Market By Product Type (Thrombin Based, Combination, Oxidized Regenerated Cellulose Based, Gelatin Based, Collagen Based Hemostat), Formulation (Matrix & Gel Hemostats , Sheet & Pad Hemostats, Sponge Hemostats, Powder Hemostats), Application (Orthopedic, General Surgery, Neurological Surgery, Cardiovascular Surgery, Reconstructive
New Study On Heart Valve Market: According to the ‘Market Growth Insight’, the Heart Valve market is anticipated to be estimated at USD XX billion along with CAGR of XX% over the forecast period 2020 - 2026. The Heart Valve study
Thursday's top analyst upgrades and downgrades included Biogen, CryoLife, Honeywell, Microsoft, Ping Identity, Qualcomm, Verizon Communications and Wendy's.
ATLANTA, Nov. 4, 2020 /PRNewswire/ -- Third Quarter and Recent Business Highlights: Achieved total revenues of $65.1 million in the third quarter 2020 versus $67.9 million in the third quarter of 2019 Total revenues decreased 4% on a GAAP and non-GAAP constant currency basis versus third…
Global Anastomosis Device Market research report has been organized with most up-to-date insight and analysis to give maximum benefits to the Healthcare industry. The report can be employed by both established and new players in the industry for complete understanding of
Adhesives and sealants are used during surgical procedures to reinforce surgical wounds, repair injured tissues, or even replace common suturing techniques. These products can be used as adjuncts to sutures to prevent air and liquid leakages. They can be developed
ATLANTA, Oct. 21, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2020 third quarter financial results will be released on Wednesday, November 4, 2020 after the market closes. On that day, the…
The market insights gained through this Tissue Regeneration Market research analysis report facilitates more defined understanding of the market landscape, issues that may interrupt in the future, and ways to position definite brand excellently. With the meticulous competitor analysis covered in this
ATLANTA, Aug. 6, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in two upcoming virtual investor conferences. CryoLife's management team will present at the upcoming…
ATLANTA, July 30, 2020 /PRNewswire/ -- Second Quarter and Recent Business Highlights: Achieved total revenues of $53.8 million in the second quarter 2020 versus $71.1 million in the second quarter of 2019 - Total revenues decreased 24% and decreased 23% on a non-GAAP constant currency…
ATLANTA, July 21, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2020 second quarter financial results will be released on Thursday, July 30, 2020 after the market closes. On that day, the…
ATLANTA, June 19, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY) ("CryoLife" or "the Company"), a leading cardiac and vascular surgery company focused on aortic disease, today announced the pricing of $100 million aggregate principal amount of 4.250% convertible senior notes due 2025…
ATLANTA , June 18, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY ) ("CryoLife" or "the Company"), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it intends to offer, subject to market conditions and other factors, $100,000,000 aggregate principal amount of convertible senior notes due 2025 (the "Notes") in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). CryoLife also intends to grant the initial purchasers of the Notes an option to purchase, within a 13-day period beginning on, and including, the date on which the Notes are first issued, up to an additional $15,000,000 aggregate principal amount of the Notes. The Notes will be senior unsecured obligations of the Company. The Notes are expected to pay interest semiannually and will mature on July 1, 2025 , unless earlier converted, redeemed or repurchased in accordance with their terms. Conversion of the Notes will be settled in cash, shares …
CryoLife (CRY) delivered earnings and revenue surprises of -500.00% and 1.26%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
ATLANTA, April 30, 2020 /PRNewswire/ -- First Quarter and Recent Business Highlights: Achieved total revenues of $66.4 million in the first quarter 2020 versus preliminary first quarter 2020 revenues of $65.5 million Total revenues decreased 2% and decreased 1% on a constant currency…
ATLANTA, Feb. 27, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today it has received CE Mark for the On-X Ascending Aortic Prosthesis (AAP), allowing resumed distribution in the European Union. The…
ATLANTA, Feb. 13, 2020 /PRNewswire/ -- Fourth Quarter and Recent Business Highlights: Total revenues were $69.7 million in the fourth quarter of 2019, reflecting year over year growth of 3% and a 4% increase on a non-GAAP constant currency basis, both compared to the fourth quarter of…
ATLANTA, Jan. 30, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2019 fourth quarter and year-end financial results will be released on Thursday, February 13, 2020 after the market closes. On…
ATLANTA, Dec. 19, 2019 /PRNewswire/ -- CryoLife, Inc. ("CryoLife"; NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has entered into an agreement whereby Misonix (NASDAQ: MSON) will have exclusive US commercialization rights for…
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the third quarter. You can find articles about an
ATLANTA, Dec. 2, 2019 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today it has received CE Mark for the E-nya thoracic stent graft system for the minimally invasive repair of lesions of the descending…
ATLANTA, Dec. 2, 2019 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has received CE Mark for the E-nside TAAA multibranch stent graft system for the endovascular treatment of thoraco-abdominal…
- ← Previous
- 1
- 2
- Next →